HER2-targeted agents and interstitial lung disease: A real-world pharmacovigilance analysis using FAERS data
Journal of Oncology Pharmacy Practice
Published online on July 07, 2025
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
IntroductionThere has been a growing concern regarding the interstitial lung disease (ILD) associated with HER2-targeted agents. This study aimed to elucidate the risk and characteristics of ILD associated with anti-HER2 agents using the FDA Adverse Event ...
IntroductionThere has been a growing concern regarding the interstitial lung disease (ILD) associated with HER2-targeted agents. This study aimed to elucidate the risk and characteristics of ILD associated with anti-HER2 agents using the FDA Adverse Event ...